Warner Chilcott U.K. Ltd is withdrawinf its application for an extension of indication for Intrinsa (testosterone) transdermal patch to include the treatment of hypoactive sexual desire disorder in menopausal women, due to commercial considerations.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.